Clinical trials: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
This study will evaluate whether adding Yiqi Fumai lyophilized injection to stable guideline-directed treatment improves symptoms, physical limitations, and NT-proBNP in adults with stable chronic heart failure caused by coronary…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
- Trial name
- NCT07803471
- Testing
- Yiqi Fumai Lyophilized Injection(YQFM), Stable Guideline-Directed Medical Therapy
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- China Academy of Chinese Medical Sciences
Chronic Total Occlusion Vessel
Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)
The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
- Trial name
- CTOHFrEF (NCT02570087)
- Testing
- chronic total coronary occlusion percutaneous intervention
- Volunteers
- 39 people
- Sponsor
- Hospital Clinic of Barcelona
Heart Failure With Reduced Ejection Fraction, Chronic Heart Failure
Vericiguat and Exercise Hemodynamics in Patients With HFrEF
Heart failure with reduced ejection fraction (HFrEF) is associated with impaired exercise capacity and abnormal exercise hemodynamics despite contemporary guideline-directed medical therapy (GDMT).
- Trial name
- EVERHETT-HF (NCT07697365)
- Testing
- Vericiguat, Guideline-directed medical therapy (GDMT) for heart failure
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Argyrios Ntalianis
Heart Failure With Reduced Ejection Fraction, Renal Insufficiency, Chronic
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
In the treatment of heart failure (HF), SGLT-2 inhibitor (SGLT-2i) can significantly improve the clinical outcome and quality of life related to HF.
- Trial name
- NCT05737186
- Testing
- SGLT-2 inhibitor
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Peking University People's Hospital
Chronic Heart Failure With Reduced Ejection Fraction
Effects of Repletion of Sodium Chloride on Natriuresis, Blood Pressure, and Neurohormonal Activity in Patients With Chronic Heart Failure With Reduced Ejection Fraction
The study is a single-center, prospective, randomized, placebo-controlled, double-blind trial conducted at the Institute of Heart Diseases and the Department of Cardiology of Wroclaw Medical University Hospital.
- Trial name
- RESALT-CHF (NCT07614295)
- Testing
- Sodium chloride supplementation
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Wroclaw Medical University
Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure
Vericiguat and Reverse Remodeling Indices in Heart Failure
The goal of this clinical trial is to investigate how vericiguat benefits adults with stable heart failure with reduced ejection fraction (HFrEF) who are already receiving guideline-directed medical therapy.
- Trial name
- VERI-PATH (NCT07405944)
- Testing
- Vericiguat, Guideline Directed Medical Therapy for Heart Failure (GDMT)
- Where
- 4 sites in Slovenia
- Volunteers
- 70 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-1-REF (NCT06215911)
- Testing
- Tovinontrine (CRD-750)
- Where
- 139 sites in United States, Australia and 17 more
- Volunteers
- 557 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals